Blood-sparing During Hip Prosthesis Surgery With Exacyl® in Patients Treated With Rivaroxaban

Inclusion Criteria: * Over 18 years of age * Scheduled to undergo elective non-traumatic primary cementless THA * Having given written informed consent to participate in the trial * Covered by Social Security Exclusion Criteria: * Rapidly destructive arthrosis of the hip * History of prior surgery on the operative hip * Contraindications to the use of tranexamic acid: * Ischaemic artery disease (angina pectoris, myocardial infarction, acute coronary syndrome or stroke) * History of venous thromboembolism * Severe renal impairment, i.e. with clearance \< 30mL/mn * Epilepsy or history of convulsions * Contraindications to the use of rivaroxaban * Severe renal failure (clearance \<30ml / min) * Cirrhotic patients with Child Pugh B * Pregnancy and breastfeeding * Cognitive disorder that precludes giving informed consent * Refusal to participate in trial * Allergy to either of the trial treatments * On-going prophylaxis of thrombosis using an agent other than rivaroxaban * On-going platelet aggregation inhibitor at a dose exceeding 125 mg daily